Acurx Pharmaceuticals, Inc. ACXP
1.02 USD -0.06 (-5.14%)
Nov 3, 2026, 3:44 PM EST
1.01 Day range 1.11
1.01 52-week range 7.54
- YTD
- -59.24%
- 1 year
- -79.94%
Financial health
Altman Z-Score
-10.22 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B-2 / 5 overall
- DCF 5
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 5
Valuation
P/E -0.5×
FY 2019 5y median -3.3× FY 2025
P/S 0.0×
FY 2019 5y median 0.0× FY 2025
P/B 0.7×
FY 2019 5y median 5.9× FY 2025
P/FCF -0.5×
FY 2019 5y median -5.0× FY 2025
EV/EBITDA 0.5×
FY 2019 5y median -2.4× FY 2025
EV/Sales 0.0×
FY 2019 5y median 0.0× FY 2025
FCF Yield -181.9%
FY 2019 5y median -20.2% FY 2025
Profitability
Gross Margin 0.0%
FY 2019 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2019 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2019 5y median 0.0% FY 2025
ROE -151.2%
FY 2019 5y median -165.3% FY 2025
ROIC -153.6%
FY 2019 5y median -165.3% FY 2025
ROA -103.6%
FY 2019 5y median -129.0% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2019 FY 2025
Operating Income 42.6%
FY 2019 FY 2025
EPS (diluted) 69.8%
FY 2019 FY 2025
Free Cash Flow 34.6%
FY 2019 FY 2025
Financial Health
Current Ratio 3.2×
FY 2019 5y median 3.2× FY 2025
Quick Ratio 3.2×
FY 2019 5y median 3.2× FY 2025
Debt / Equity 0.0×
FY 2019 5y median 0.0× FY 2025
Net Debt / EBITDA 0.9×
FY 2019 5y median 0.8× FY 2025
Interest Coverage 0.0×
FY 2019 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31